| Date: | 6/10/2022 |
|-------------------------------|---|
| Your Name: | Anthony Lollo |
| Manuscript Title: | Long-term Continuity of Coverage Among Medicaid Beneficiaries |
| Manuscript Number (if known): | M22-1313 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|-------------|---|---|
| | | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | None | Click the tab key to add additional rows. |
| 2 | Grants or | \boxtimes | None | |
| | contracts from | | | |
| | any entity (if not indicated in item | | | |
| | #1 above). | | | |
| | | | | |
| 3 | Royalties or licenses | | None | |
| | | | | |
| | | | | |
| | | | | |

| | | Name all entities with whom you have thisSpecifications/Comments (e.g., if payments vrelationship or indicate none (add rows as needed)made to you or to your institution) | vere |
|----|---|--|------|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | ☑ None □ □ □ □ □ □ □ □ | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☑ None | |
| 13 | Other financial or non-financial interests | None Anthony Lollo is currently employed by CVS Health | |
| Plea × | - | t to the following statement to indicate your agreeme answered every question and have not altered the wo | |

| Date: | 6/14/2022 |
|-------------------------------|--|
| Your Name: | Mark Schlesinger |
| Manuscript Title: | Long-term Continuity of Coverage Among Medicaid Beneficiaries" |
| Manuscript Number (if known): | M22-1313 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning c | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | Chima Ndumele PI Click the tab key to add additional rows. |
| | | Time frame: past 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | CAHPS Cooperative Agreement Patient Narratives About Diagnostic Errors |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None University of New Mexico | Co-directing Qualitative Research Training |
| 6 | Payment for expert testimony | None Legal Case in Canada | Involved advertising bans for dentists |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | ☑ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ⊠ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None Board Member | Community Catalyst |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|---|---|
| 11 | Stock or stock options | ☑ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☑ None | |
| 13 | Other financial or non-financial interests | ☑ None | |
| Plea × | - | t to the following statement to indicate your agreeme answered every question and have not altered the wo | |



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your

Royalties: Funds are coming in to you or your institution due to your patent



| Section 1. | Identifying Inform | mation | |
|--|---------------------------|----------------------------------|--|
| 1. Given Name (Fii Harlan | rst Name) | 2. Surname (Last Nam Krumholz | e) 3. Date 28-June-2022 |
| 4. Are you the corresponding author? | | Yes 🖌 No | Corresponding Author's Name Chima Ndumele |
| 5. Manuscript Title Long-term Conti | | ong Medicaid Beneficia | aries |
| 6. Manuscript Ider M22-1313 | ntifying Number (if you k | now it) | |

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

🖌 No

Are there any relevant conflicts of interest? Yes

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

No

Are there any relevant conflicts of interest? \checkmark Yes

If yes, please fill out the appropriate information below.

| Name of Entity | Grant? | Personal Fees? | Non-Financial Support? | Other? | Comments | |
|--------------------------|--------|-------------------|---------------------------|--------|---|--|
| UnitedHealth | | \checkmark | | | Chair, Cardiac Scientific Advisory Board | |
| Tesseract/4Catalyst | | \checkmark | | | Consultant | |
| Element Science | | \checkmark | | | Member, Advisory Board | |
| Aetna | | \checkmark | | | Member, Physician Advisory Board | |
| Reality Labs | | \checkmark | | | Member, Advisory Board | |
| F-Prime | | \checkmark | | | Consultant | |
| Arnold & Porter Law Firm | | \checkmark | | | Sanofi clopidogrel litigation | |



| Name of Entity | Grant? | Personal Fees ? | Non-Financial Support? | Other? | Comments | |
|--|--------------|---------------------------|---------------------------|--------------|--|--|
| Martin/Baughman Law Firm | | \checkmark | | | Cook Celect IVC filter litigation | |
| Siegfried & Jensen Law Firm | | \checkmark | | | Vioxx litigation | |
| HugoHealth | | | | \checkmark | Co-founder of HugoHealth, a personal health information platform | |
| Refactor Health | | | | \checkmark | Co-founder of Refactor Health, an enterprise healthcare Al-augmented data management company | |
| Centers for Medicare & Medicaid Services | | | | \checkmark | Association with contracts, through Yale New Haven Hospital, to develop and maintain measures of hospital performance | |
| Johnson & Johnson | \checkmark | | | | Association with research grants, through Yale University, to develop methods of clinical trial data sharing | |
| Massachusetts Medical Society | | \checkmark | | | Co-Editor, Journal Watch Cardiology | |

Section 4.

Intellectual Property -- Patents & Copyrights

| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? 🗌 Ye | Do you | have any patents | whether planned | , pending or issu | ied, broadly releva | ant to the work? | Yes |
|---|--------|------------------|-----------------|-------------------|---------------------|------------------|-----|
|---|--------|------------------|-----------------|-------------------|---------------------|------------------|-----|

| 1 | No |
|---|----|
| | |

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Krumholz reports personal fees from UnitedHealth, personal fees from Tesseract/4Catalyst, personal fees from Element Science, personal fees from Aetna, personal fees from Reality Labs, personal fees from F-Prime, personal fees from Arnold & Porter Law Firm, personal fees from Martin/Baughman Law Firm, personal fees from Siegfried & Jensen Law Firm, cofounder of HugoHealth, co-founder of Refactor Health, association with contracts, through Yale New Haven Hospital, from the Centers for Medicare & Medicaid Services, association with grants, through Yale University, from Johnson & Johnson, personal fees from Massachusetts Medical Society, outside the submitted work;.

Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.

| Date: | 6/15/2022 |
|-------------------------------|---|
| Your Name: | Jacob Wallace |
| Manuscript Title: | Long-term Continuity of Coverage Among Medicaid Beneficiaries |
| Manuscript Number (if known): | M22-1313 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | Time frame: Since the initial planning of the work | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None Arnold Ventures Commonwealth Fund | Funded research unrelated to this work. Funded research unrelated to this work. |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have thisSpecifications/Comments (e.g., if payments wrelationship or indicate none (add rows as needed)made to you or to your institution) | /ere |
|----|---|--|------|
| 4 | Consulting fees | None None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None Image: I | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|---|--|---|
| 11 | Stock or stock options | ☑ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☑ None | |
| 13 | Other financial or non-financial interests | None Aurrera Health Group | Spouse is the Senior Director of Medicaid Policy and Financing at a Medicaid-focused consulting group |
| Plea 🖂 | Please place an "X" next to the following statement to indicate your agreement: | | |

| Date: | 7/5/2022 |
|-------------------------------|---|
| Your Name: | Chima Ndumele |
| Manuscript Title: | Long-term Continuity of Coverage Among Medicaid Beneficiaries |
| Manuscript Number (if known): | M22-1313 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|---|
| | Time frame: Since the initial planning of the work | | | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | None | Click the tab key to add additional rows. |
| | | | Time frame: past 36 months | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | None | |
| 3 | Royalties or licenses | | None | |

| | | Name all entities with whom you have thisSpecifications/Comments (e.g., if payments wrelationship or indicate none (add rows as needed)made to you or to your institution) | /ere |
|----|---|--|------|
| 4 | Consulting fees | None None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None Image: I | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 11 | Stock or stock options | ☑ None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☑ None | |
| 13 | Other financial or non-financial interests | ☑ None | |
| Please place an "X" next to the following statement to indicate your agreement: | | | |